Healthcare / Drug Manufacturers - GeneralCopenhagen
$284.90
-8.05 (-2.75%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $69.7B · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.26T
P/E
10.4x
↓EV/EBITDA
8.8x
↓ROE
52.8%
↑Gross Margin
81.0%
↑Debt/Equity
0.67
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+20.4%
FCF CAGR
-23.3%
FCF margin
9.4%
FCF / Net income
0.28x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $309.06B · net income $102.43B · FCF $28.99B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $309.06B | $309.06B | $290.40B | $232.26B | $176.95B |
| Net Income | $102.43B | $102.43B | $100.99B | $83.68B | $55.52B |
| EBITDA | $156.73B | $156.73B | $147.94B | $114.63B | $76.80B |
| EPS | 23.03 | 23.03 | 22.63 | 18.62 | 12.22 |
| Gross Margin | 81.0% | 81.0% | 84.7% | 84.6% | 83.9% |
| Operating Margin | 41.3% | 41.3% | 44.2% | 44.2% | 42.3% |
| Net Margin | 33.1% | 33.1% | 34.8% | 36.0% | 31.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.67 | 0.67 | 0.72 | 0.25 | 0.31 |
| Current Ratio | 0.79 | 0.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $28.99B | $28.99B | $69.66B | $70.01B | $64.13B |
| Returns | |||||
| ROE | 52.8% | 52.8% | 70.4% | 78.5% | 66.5% |
| Valuation | |||||
| P/E | 10.39 | 10.39 | 28.17 | 38.98 | 39.59 |
| EV/EBITDA | 8.75 | 8.75 | 19.82 | 28.57 | 28.80 |
| P/B | 6.53 | 6.53 | 19.83 | 30.61 | 26.33 |
| Growth & Yield | |||||
| Revenue Growth | 6.4% | 6.4% | 25.0% | 31.3% | — |
| EPS Growth | 1.8% | 1.8% | 21.5% | 52.4% | — |
| Dividend Yield | 5.4% | 5.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
3.2%
EPS terminal req.
$25.28
Spread vs growth
-1.4%
5Y implied EPS CAGR
5.8%
EPS terminal req.
$30.59
Spread vs growth
-4.1%
10Y implied EPS CAGR
7.9%
EPS terminal req.
$49.26
Spread vs growth
-6.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.7%
Start / end P/E
19.7x → 12.4x
EPS bridge
22.63 → 23.03
Residual
-0.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.